266 related articles for article (PubMed ID: 38494848)
1. The cell death-related genes machine learning model for precise therapy and clinical drug selection in hepatocellular carcinoma.
Du M; Qu Y; Qin L; Zheng J; Sun W
J Cell Mol Med; 2024 Apr; 28(7):e18168. PubMed ID: 38494848
[TBL] [Abstract][Full Text] [Related]
2. Multiple programmed cell death patterns and immune landscapes in bladder cancer: Evidence based on machine learning and multi-cohorts.
Li Z; Li Y; Liu L; Zhang C; Li X
Environ Toxicol; 2024 Mar; 39(3):1780-1801. PubMed ID: 38064272
[TBL] [Abstract][Full Text] [Related]
3. Identification of PANoptosis-related subtypes, construction of a prognosis signature, and tumor microenvironment landscape of hepatocellular carcinoma using bioinformatic analysis and experimental verification.
Ouyang G; Li Q; Wei Y; Dai W; Deng H; Liu Y; Li J; Li M; Luo S; Li S; Liang Y; Pan G; Yang J; Gan T
Front Immunol; 2024; 15():1323199. PubMed ID: 38742112
[TBL] [Abstract][Full Text] [Related]
4. Identifying the programmed cell death index of hepatocellular carcinoma for prognosis and therapy response improvement by machine learning: a bioinformatics analysis and experimental validation.
Shi Y; Feng Y; Qiu P; Zhao K; Li X; Deng Z; Wang J
Front Immunol; 2023; 14():1298290. PubMed ID: 38170006
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
6. Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.
Wei J; Wang J; Chen X; Zhang L; Peng M
PeerJ; 2024; 12():e16819. PubMed ID: 38317842
[TBL] [Abstract][Full Text] [Related]
7. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
8. A programmed cell death-related model based on machine learning for predicting prognosis and immunotherapy responses in patients with lung adenocarcinoma.
Zhang Y; Wang Y; Chen J; Xia Y; Huang Y
Front Immunol; 2023; 14():1183230. PubMed ID: 37671155
[TBL] [Abstract][Full Text] [Related]
9. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
Wang L; Wang L; He P
Front Genet; 2022; 13():1064432. PubMed ID: 36568383
[No Abstract] [Full Text] [Related]
11. Comprehensive analysis of diverse programmed cell death patterns in the prognosis, tumor microenvironment and drug sensitivity in hepatocellular carcinoma.
Yu Y; Lou Y; Zhu J; Wang X
Medicine (Baltimore); 2023 Dec; 102(48):e36239. PubMed ID: 38050240
[TBL] [Abstract][Full Text] [Related]
12. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.
Wang J; Ling S; Ni J; Wan Y
BMC Cancer; 2022 Jun; 22(1):638. PubMed ID: 35681134
[TBL] [Abstract][Full Text] [Related]
13. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
14. Identification of prognostic biomarkers for cervical cancer based on programmed cell death-related genes and assessment of their immune profile and response to drug therapy.
Feng S; Wang Z; Zhang H; Hou B; Xu Y; Hao S; Lu Y
J Gene Med; 2024 Jan; 26(1):e3643. PubMed ID: 38044747
[TBL] [Abstract][Full Text] [Related]
15. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
16. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
Jiang H; Chen H; Wang Y; Qian Y
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
[TBL] [Abstract][Full Text] [Related]
17. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic role and immune correlates of programmed cell death-related genes in hepatocellular carcinoma.
He Z; Zhang J; Huang W
Sci Rep; 2023 Nov; 13(1):20509. PubMed ID: 37993470
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive genomic signature of pyroptosis-related genes and relevant characterization in hepatocellular carcinoma.
Wang S; Gao S; Shan L; Qian X; Luan J; Lv X
PeerJ; 2023; 11():e14691. PubMed ID: 36650832
[TBL] [Abstract][Full Text] [Related]
20. Identification an innovative classification and nomogram for predicting the prognosis of thyroid carcinoma patients and providing therapeutic schedules.
Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14817-14831. PubMed ID: 37596371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
